TARRYTOWN, N.Y., Dec. 20, 2010 /PRNewswire-FirstCall/ —
Regeneron Pharmaceuticals, Inc. (Nasdaq:
REGN) today announced that it will hold a teleconference and
webcast at 8:30 a.m. Eastern Time on Monday, December 20, to
discuss results of the Phase 3 COPERNICUS study with VEGF Trap-Eye
in central retinal vein occlusion (CRVO) and the week 52 follow-up
results of the Phase 2 DA VINCI study in patients with diabetic
macular edema (DME). A press release will be issued prior to
the call.
Teleconference/Webcast Details To participate in the live
call on Monday, December 20, at 8:30 a.m. Eastern Time, please dial
(877) 390-5538 for domestic callers and (408) 940-3843 for
international callers, participant code 33105543. The live
conference call is being webcast and it can be accessed on the
“Newsroom” page of the Company’s web site, www.regeneron.com. The
webcast will be available for 30 days following the call.About
Regeneron PharmaceuticalsRegeneron is a fully integrated
biopharmaceutical company that discovers, develops, and
commercializes medicines for the treatment of serious medical
conditions. In addition to ARCALYST® (rilonacept)
Injection for Subcutaneous Use, its first commercialized product,
Regeneron has therapeutic candidates in Phase 3 clinical trials for
the potential treatment of gout, diseases of the eye (wet
age-related macular degeneration and central retinal vein
occlusion), and certain cancers. Additional therapeutic
candidates developed from proprietary Regeneron technologies for
creating fully human monoclonal antibodies are in earlier stage
development programs in rheumatoid arthritis and other inflammatory
conditions, pain, cholesterol reduction, allergic and immune
conditions, and cancer. Additional information about
Regeneron and recent news releases are available on Regen
‘/>”/>
